

Trust Headquarters
 Russell's Hall Hospital
 Dudley
 West Midlands
 DY1 2HQ

Ref: FOI-042026-0002381

Date: 18.5.26

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

I have a freedom of information request regarding the treatment of Multiple Myeloma. Could you please answer the following questions.

Q1. Of the multiple myeloma patients over the past 3 months, how many were treated with the following:

- Belantamab Mafodotin [Blenrep] 0
- Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone 4
- Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone 0
- Bortezomib [Velcade] ± Dexamethasone 1
- Bortezomib [Velcade] + Melphalan + Prednisolone/Dexamethasone (VMp or VCd) 2
- Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) 0
- Carfilzomib [Kyprolis] + Dexamethasone 0
- Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) 0
- Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) 15
- Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) 3
- Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) 38
- Daratumumab [Darzalex] monotherapy 3
- Elranatamab 0
- Idecabtagene vicleucel [Abecma] 0
- Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) 2
- Isatuximab [Sarclisa] + Pomalidomide [Imnovid] + Dexamethasone (IsaPd) 2
- Ixazomib [Ninlaro] + Lenalidomide [Revlimid] + Dexamethasone (IRd) 1
- Lenalidomide [Revlimid] + Dexamethasone 21
- Lenalidomide [Revlimid] monotherapy 13
- Panobinostat + Bortezomib + Dexamethasone 2
- Pomalidomide [Imnovid] + Dexamethasone 5
- Selinexor + Bortezomib [Velcade] + Dexamethasone 0
- Selinexor + Dexamethasone 2
- Talquetamab 4
- Teclistamab [Tecvayli] 3
- Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify]
 - Isatuximab [Sarclisa] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) 1
 - Melphalan 5

Q2. In the last 6 months, how many patients have been initiated* on the following regimens?

- Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone 3
- Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone 0
- Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) 0
- Carfilzomib [Kyprolis] + Dexamethasone 0
- Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) 0
- Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) 3
- Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) 3
- Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) 11
- Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) 3
- Lenalidomide [Revlimid] monotherapy 1
- Lenalidomide [Revlimid] + Dexamethasone 2
- Selinexor + Bortezomib [Velcade] + Dexamethasone 0
- Selinexor + Dexamethasone 1
- Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify]
14 other initiated, Talquetamab – 4, other regimens all 1 patient each

*Patients are considered initiated if they have not received any of the drugs in the named regimen (either alone or in combination) in the 6 months prior to initiation.

Q3. In the last 6 months, how many patients have received the following second-line treatment?

- Lenalidomide [Revlimid] + Dexamethasone 1

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dqft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust